 There are multiple bear arguments floating around as reasons to sell Moderna NASDAQ: MRNA, one of the drugmakers leading the way to develop a coronavirus vaccine. Moderna lost a petition trying to invalidate patents held by Arbutus Biopharma NASDAQ: ABUS: The patents are unlikely to keep Modernas coronavirus vaccine, mRNA-1273, off the market. The biggest impact would be Moderna having to pay royalties to Arbutus on sales of mRNA-1273. 